Search

BIO DESIGN

pISSN 2288-6982
eISSN 2288-7105

Article

Article Tools

Share this article on :

Stats or metrics

Article

Mini review

BioDesign 2022; 10(1): 1-7

Published online March 30, 2022

https://doi.org/10.34184/kssb.2022.10.1.1

© Korean Society for Structural Biology

Current understanding of SARS-CoV-2 papain-like protease inhibitors

Minhyeong Choi1, Sangwoo Kang2, Ane Martiartu3 and Donghyuk Shin1,*

1Department of Systems Biology, College of Life Science and Biotechnology, Yonsei University, Seoul 03722, Republic of Korea
2Division of Bioengineering, Incheon National University, Incheon 22012, Republic of Korea
3Department of Biotechnology, College of Life Science and Biotechnology, Yonsei University, Seoul 03722, Republic of Korea

Correspondence to: *donghyuk.shin@yonsei.ac.kr

Received: November 19, 2021; Revised: December 24, 2021; Accepted: December 27, 2021

Abstract

The spread of SARS-CoV-2 has been the cause of the ongoing COVID-19 global pandemic, which has increased morbidity and mortality worldwide. SARS-CoV-2 has two proteases that play an essential role in its spread, promoting replication by cleaving viral polyproteins. One of these two proteases, PLpro suppresses the host immune response through deubiquitination and deISGylation. Since PLpro plays a vital role in viral spread, there is a need for research on therapeutic agents that target it. In this review, we identify and classify several types of PLpro inhibitors.